Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22081
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiamopoulou, A.en
dc.contributor.authorChalla, A.en
dc.contributor.authorKapoglou, P.en
dc.contributor.authorCholevas, V.en
dc.contributor.authorMavridis, A. K.en
dc.contributor.authorLapatsanis, P. D.en
dc.date.accessioned2015-11-24T19:21:04Z-
dc.date.available2015-11-24T19:21:04Z-
dc.identifier.issn0171-967X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22081-
dc.rightsDefault Licence-
dc.subjectAbsorptiometry, Photonen
dc.subjectAdministration, Intranasalen
dc.subjectAdolescenten
dc.subjectAlkaline Phosphatase/blooden
dc.subjectArthritis, Juvenile Rheumatoid/*drug therapy/metabolism/physiopathologyen
dc.subjectBiological Markers/blood/urineen
dc.subjectBone Density/drug effectsen
dc.subjectBone Resorption/drug therapy/metabolismen
dc.subjectCalcitonin/administration & dosage/*therapeutic useen
dc.subjectCalcium/metabolism/therapeutic useen
dc.subjectDietary Supplementsen
dc.subjectHumansen
dc.subjectJoints/physiopathologyen
dc.subjectLumbar Vertebrae/metabolism/radiographyen
dc.subjectOsteocalcin/blooden
dc.subjectSeverity of Illness Indexen
dc.subjectTreatment Outcomeen
dc.titleEffects of intranasal salmon calcitonin in juvenile idiopathic arthritis: an observational studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11685430-
heal.identifier.secondaryhttp://www.springerlink.com/content/ca9wn0nt10ju07qa/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2001-
heal.abstractThe aim of this study was to follow the changes in bone mineral density (BMD) and biochemical markers of bone turnover in 10 children (7.5-17.5 years of age) with severe juvenile idiopathic arthritis (JIA), during a 3-year therapy with salmon calcitonin (100 IU/day 2 months on and 2 off for a year and 200 IU/day for 2 years) and calcium (500 mg/day). All patients were functional classes III and IV and were measured at yearly intervals with a dual photon absorptiometer at the lumbar spine. The changes observed were 7.2-9.5% per year for BMD and 2.0-6.0% for volumetric bone mineral density (BMDvol). The bone resorption markers showed significant decreases after a year's treatment (Pyr/Cr from 175+/-15 to 108+/-15 nm/mm, P < 0.001, Pyr-D/Cr from 24.3+/-3.5 to 13.3+/-1.9 nm/mm, P < 0.05, and OHPr/Cr from 57.4+/-11 to 35.1+/-8.4 microg/mg) and smaller changes thereafter. No significant changes were observed in the bone formation markers of osteocalcin and alkaline phosphatase. Serum iPTH, the vitamin D metabolites, and calcium concentrations fluctuated within normal, while calcium excretion increased from 0.3+/-0.1 to 1.9+/-0.4 mg/kg/24 hours, P < 0.001. In conclusion, the present study, despite its limitations of not being placebo controlled, shows possible beneficial effects of intranasal calcitonin on bone resorption and pain relief in JIA patients.en
heal.journalNameCalcif Tissue Inten
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Siamopoulou-2001-Effects of intranasa.pdf139.62 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons